• DOI:10.1158/0008-5472.CAN-08-1740
Corpus ID: 14354934

Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235.

@article{Eichhorn2008Phosphatidylinositol3H,
  title={Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235.},
  author={P. Eichhorn and M. Gili and M. Scaltriti and V. Serra and M. Guzm{\'a}n and Wouter Nijkamp and R. Beijersbergen and V. Valero and J. Seoane and R. Bernards and J. Baselga},
  journal={Cancer research},
  year={2008},
  volume={68 22},
  pages={
          9221-30
        }
}

P. Eichhorn, M. Gili, +8 authors J. Baselga

Published 2008

Medicine

Cancer research

Small molecule inhibitors of HER2 are clinically active in women with advanced HER2-positive breast cancer who have progressed on trastuzumab treatment. However, the effectiveness of this class of agents is limited by either primary resistance or acquired resistance. Using an unbiased genetic approach, we performed a genome wide loss-of-function short hairpin RNA screen to identify novel modulators of resistance to lapatinib, a recently approved anti-HER2 tyrosine kinase inhibitor. Here, we… CONTINUE READING

View PDF

Save to Library

Create Alert

Cite

Launch Research Feed